Mental Health
News Category
Quantum BioPharma Showcases MS Drug Candidate and Growth Strategy in Executive Podcast
Quantum BioPharma's executive co-chairman appeared on the BioMedWire Podcast to discuss the company's lead MS drug candidate Lucid-MS and its alcohol ...
Onco-Innovations Advances ONC010 Manufacturing Development With Nanosoft
Onco-Innovations Limited initiates polymer process development with Nanosoft Polymers to establish a scalable, reproducible platform for its lead nano...
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Amid Pivotal Phase 3 Alzheimer’s Study
Annovis Bio promotes Dr. Cheng Fang to Chief Scientific Officer, positioning him to lead scientific strategy as the company approaches top-line data f...
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
GeoVax comments on recent U.S. government procurement of smallpox vaccine ACAM2000, reinforcing the strategic importance of sustained investment in or...
Next-Generation Precision Obesity Models Aim to Close Translational Gap in Anti-Obesity Drug Development
Protheragen Obesity introduces tiered, customizable preclinical models including gene-edited and humanized platforms to improve predictive accuracy fo...
Helix BioPharma Strengthens Executive Leadership Ahead of U.S. Listing and Clinical Advancement
Helix BioPharma appoints Helen Middleton as General Counsel and David Browning as VP of Clinical Operations to support its planned U.S. exchange listi...
HeartBeam Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study
HeartBeam (NASDAQ: BEAT) has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study for heart attack detection using its 3D ECG t...
Onco-Innovations Advances Manufacturing and Development of Novel PNKP Inhibitors for Hard-to-Treat Cancers
Onco-Innovations Ltd. is making progress in the development of PNKP inhibitors, a new class of DNA damage response therapies, with a key manufacturing...
FDA-Approved Drug May Enhance Immunotherapy for Rare Liver Cancer
Researchers at the University of Washington discovered that an existing FDA-approved drug could improve immunotherapy outcomes for fibrolamellar carci...
Silo Pharma Advances SPC-15 Intranasal PTSD Program With Device Robustness Study
Silo Pharma's partner Resyca will conduct a robustness study on the nasal spray device for SPC-15, supporting regulatory guidance for Phase 1 trials a...
HeartBeam Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study
HeartBeam Inc. completed patient enrollment early in its ALIGN-ACS pilot study, evaluating its 3D ECG technology for heart attack detection, potential...
Creative Biolabs Offers Custom Oligosaccharide Synthesis and Glycan Characterization to Accelerate Drug Discovery
Creative Biolabs combines advanced synthesis and analytical platforms to provide structurally validated oligosaccharides, addressing challenges in gly...
Amerigo Scientific Launches High-Quality iPSC-Derived Cells to Boost Biomedical Research and Cell Therapy Development
Amerigo Scientific releases premium iPSC-derived cells and engineered reporter lines, offering robust tools for disease modeling, drug screening, and ...
Ace Therapeutics Launches Comprehensive Preclinical Pain Research Platform to Accelerate Analgesic Drug Development
Ace Therapeutics announces full-spectrum preclinical analgesic drug development services with validated in vivo pain models and integrated research ca...
Lifespan Edge Expands Longevity Clinics to Florida and Maryland
Lifespan Edge opens new clinics in West Palm Beach and Columbia, bringing concierge-style longevity care and advanced diagnostics to more patients, wh...
Quantum BioPharma Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
Quantum BioPharma's collaborative imaging study with Massachusetts General Hospital has reached the halfway point in patient enrollment, with early re...
Cardio Diagnostics Holdings Brings Molecular Precision to Coronary Heart Disease Detection
Cardio Diagnostics Holdings (NASDAQ: CDIO) introduces epigenetic and genetic tests to address the blind spot in coronary heart disease detection, wher...
New American Heart Association Grants Fund Pioneering Cardiac Arrest Research
The American Heart Association has awarded $3.4 million in grants to two research teams in New York and Oregon to lead studies aimed at improving card...
Oncotelic Therapeutics Publishes Peer-Validation of Deciparticle Platform for Intravenous Drug Delivery
Oncotelic Therapeutics and Sapu Nano announced the publication of a peer-reviewed manuscript validating the Deciparticle nanoparticle platform, with i...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Tonix Pharmaceuticals Enrolls First Patient in Phase 2 Trial of TNX-102 SL for Major Depressive Disorder
Tonix Pharmaceuticals has enrolled the first patient in its HORIZON Phase 2 trial evaluating TNX-102 SL as a first-line monotherapy for major depressi...
Global Experts Update Heart Failure Definition to Improve Prevention, Diagnosis and Care
A new international consensus document refines the definition and classification of heart failure, emphasizing early detection, personalized treatment...
Annovis Bio Raises $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Therapies
Annovis Bio announced a $3.4 million registered direct offering led by H.C. Wainwright, with proceeds for working capital, signaling continued investo...
Aditxt Subsidiary Pearsanta Begins Enrollment in Clinical Study for Blood-Based Endometriosis Test
Pearsanta Inc., a subsidiary of Aditxt Inc., has initiated enrollment in a clinical study to validate its Mitomic Endometriosis Test, a non-invasive b...
NanoViricides to Present at PODD 2025 Conference, Highlighting Broad-Spectrum Antiviral Pipeline
NanoViricides will present updates on its antiviral drug pipeline and platform technologies at the PODD 2025 Conference, with lead candidate NV-387 ad...
GeoVax Highlights IDSA Guidance Underscoring Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
GeoVax Labs emphasizes new IDSA guidelines that reveal current COVID-19 vaccines provide inadequate protection for immunocompromised individuals, vali...
Soligenix Research Demonstrates High-Temperature Stability for Ebola and Marburg Vaccines, Addressing Critical Cold Chain Issues
Soligenix published peer-reviewed data showing its ThermoVax platform maintains stability for Ebola and Marburg vaccines at temperatures above 40°C, p...
GeoVax Highlights Alignment of GEO-CM04S1 Clinical Data with New IDSA Guidelines for Immunocompromised COVID-19 Vaccination
GeoVax's Phase 2 data for its multi-antigen COVID-19 vaccine GEO-CM04S1 aligns with new IDSA guidelines calling for improved vaccines for immunocompro...
NanoViricides CEO Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
NanoViricides' lead candidate NV-387 shows strong anti-measles activity in preclinical models, extending survival by 130% and protecting lung tissue, ...
Lifordi Immunotherapeutics Presents Nonclinical Data on LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis
Lifordi Immunotherapeutics announced the initiation of a Phase 1 study for its glucocorticoid antibody-drug conjugate LFD-200 in rheumatoid arthritis,...
NanoViricides to Present at Spartan Capital Investor Conference 2025
NanoViricides will present at the Spartan Capital Investor Conference, highlighting its broad-spectrum antiviral drug NV-387 and other pipeline candid...
NanoViricides Sets Date for 2025 Annual Shareholders Meeting
NanoViricides announced its 2025 Annual Shareholders Meeting will be held on November 8, 2025, in Stamford, Connecticut, as the company progresses its...
Annovis Bio Completes Site Activation and First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Annovis Bio announces that all 84 U.S. sites for its pivotal Phase 3 Alzheimer’s trial are activated and enrolling, with first patients completing the...
Surface Sugars on Immune Cells Linked to the Progression of Psoriasis
A new study reveals that immune cells shed surface sugars before entering inflamed skin in psoriasis patients, offering insights into disease progress...
First-in-Human CRISPR Gene-Editing Therapy Safely Lowers Cholesterol and Triglycerides in Early Trial
A Phase 1 trial of a CRISPR-Cas9 therapy targeting ANGPTL3 safely reduced LDL cholesterol and triglycerides by nearly 50% or more, offering a potentia...
PCSK9 Inhibitor Reduces First Major Cardiovascular Events in High-Risk Adults Without Prior Heart Attack or Stroke
The VESALIUS-CV trial shows that adding evolocumab to high-intensity lipid-lowering therapy reduces the risk of coronary heart disease death, heart at...
Daily Pill Enlicitide Lowers LDL Cholesterol as Effectively as Injectable PCSK9 Inhibitors, Study Finds
A phase 3 trial presented at the American Heart Association’s Scientific Sessions 2025 shows that the oral medication enlicitide reduces LDL cholester...
Standard Care Outperforms Catheter Procedure for High-Risk AFib Patients, Study Finds
A new study presented at the American Heart Association’s Scientific Sessions 2025 found that for older patients with atrial fibrillation at high risk...
Daily Cup of Coffee Linked to Lower Recurrence of Atrial Fibrillation in New Trial
A study presented at the American Heart Association's Scientific Sessions 2025 found that adults with atrial fibrillation who drank one cup of caffein...
GeoVax Recognizes World Immunization Day, Stresses Need for Innovation and Trust in Vaccines
GeoVax Labs highlights its diversified vaccine platforms and commitment to restoring public trust on World Immunization Day, addressing the gap betwee...
Polypill for Heart Failure Improves Heart Function, Symptoms and Quality of Life
A study presented at the American Heart Association’s Scientific Sessions 2025 found that a once-daily polypill combining three heart failure medicati...
NanoViricides Receives Regulatory Approval to Begin Phase II Trial of NV-387 for MPox in the DRC
NanoViricides has received approval from the DRC’s regulatory agency to start a Phase II trial of its broad-spectrum antiviral NV-387 for MPox, markin...
Oragenics Regains NYSE Compliance, Advances Concussion Trial, and Expands AI-Driven Neurology Pipeline
Oragenics Inc. regained NYSE American compliance, progressed its Phase IIa trial for concussion treatment ONP-002, and launched an AI collaboration wi...
Annovis Bio Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances
Annovis Bio announced full activation of all 84 sites in its Phase 3 Alzheimer’s study and promising biomarker data, positioning it for NDA submission...
NanoViricides Closes $6 Million Registered Direct Offering to Fund Working Capital and General Corporate Purposes
NanoViricides announced the closing of a $6 million registered direct offering with a healthcare institutional investor, including warrants, to suppor...
Creative Biolabs' Customized CRO Solutions Address Enterococcus Safety Challenges in LBP Development
Creative Biolabs launches tailored Enterococcus microbiome CRO services to overcome safety assessment bottlenecks, including virulence and antibiotic ...
Understanding the Research Implications of Tirzepatide, Retatrutide, and Glutathione in Metabolic and Regenerative Studies
This article examines the mechanisms, formulations, and research considerations of key peptides—tirzepatide, retatrutide, and glutathione—highlighting...
Tesamorelin vs Sermorelin: Key Differences in Peptide Research Applications
This article compares Tesamorelin and Sermorelin, highlighting their distinct structural, pharmacological, and biological profiles for researchers sel...